Murrough, J W
Collins, K A
Fields, J
DeWilde, K E
Phillips, M L
Mathew, S J
Wong, E
Tang, C Y
Charney, D S
Iosifescu, D V
Article History
Received: 17 September 2014
Revised: 22 November 2014
Accepted: 19 December 2014
First Online: 17 February 2015
Competing interests
: In the past 3 years, JWM has served on advisory boards for Janssen Research and Development and Genentech, has provided consultation services for ProPhase, LLC and Impel Neuropharma and has received research support from Janssen and Avanir Pharmaceuticals; he is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders. DVI has consulted for Avanir, CNS Response, INSYS Therapeutics, Lundbeck, Otsuka, Servier, Sunovion and he has received grant/research support through Mount Sinai School of Medicine from Alkermes, AstraZeneca, Brainsway, Euthymics Bioscience, Neosync, Roche and Shire. DSC (Dean of Icahn School of Medicine at Mount Sinai) and Icahn School of Medicine at Mount Sinai have been named on a use patent on ketamine for the treatment of depression. The Icahn School of Medicine has entered into a licensing agreement for the use of ketamine as therapy for treatment-resistant depression. DSC and Icahn School of Medicine at Mount Sinai could potentially benefit if ketamine were to gain approval for the treatment of depression. DSC is named on a patent pending for ketamine as a treatment for PTSD and for neuropeptide Y as a treatment for mood and anxiety disorders; he has received funding from the U.S. Department of Defense, NIH, NIH/NIMH, NARSAD, USAMRAA; he has severed on the scientific advisory board for the Institute of Medicine Committee on DHS Workforce Resilience and on the editorial board of CNS Spectrums. SJM has received consulting fees from Bristol-Myers Squibb, Cerecor, Genentech and Naurex, and research support from AstraZeneca, Janssen Research and Development, and Otsuka. The remaining authors declare no conflict of interest.